Updates are available Correction dated 2020-10-07

Article History

First Online: 11 July 2020

Change Date: 7 October 2020

Change Type: Correction

Change Details: The article ���Hepatitis B Core Antibody: Role in Clinical Practice in 2020,��� written by Robert G. Gish, Syed Abdul Basit, John Ryan, Altaf Dawood, and Ulrike Protzer, was originally published Online First without Open Access. After publication in volume 19, issue 3, pages 254���265, the author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to �� The Author(s) 2020, and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons License, and indicate if changes were made. The images or other third party materials in this article are included in the article���s Creative Commons License, unless indicated otherwise in a credit line to the material. If material is not included in the article���s Creative Commons License and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

Change Details: http://creativecommons.org/licenses/by/4.0/

Change Details: .

Compliance with Ethical Standards

:

: No relevant disclosures for Abdul Basit, Ryan, or Dawood. Dr. Protzer has disclosed that she has been an Advisor of AbbVie, Dicerna, GSK, MSD, and Vaccitech; has current activity with the scientific or clinical advisory boards of Arbutus Biopharma and Gilead; received scientific funding from Alios-J&J, Roche, and VIR Biotechnology; has been a member of the supervisory board, and is the cofounder, board member, and receives grant support from SCG Cell Therapy. Dr. Gish has disclosed that he has received grant support from Gilead; has been a consultant and/or advisor to Abbott, AbbVie, Access Biologicals, Alexion, Antios, Arrowhead Research Corporation, Bayer AG, Bristol-Myers Squibb, Eiger, Eisai, Enyo Pharma, eStudySite, Forty-Seven Inc., Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTX, HepQuant, Intercept, Ionis Pharmaceuticals, Janssen, Laboratory for Advanced Medicine, Lilly, Merck, Salix, Shionogi, Trimaran, Viking Therapeutics; has current activity with the scientific or clinical advisory boards of Abbott, AbbVie, Arrowhead, Bayer, Dova Pharmaceuticals, Eiger, Enyo, Hatch BioFund, HepQuant, Intercept, Janssen, and MedImmune; is an advisory consultant for Biocollections, Fujifilm/Wako, and Quest; is on the Data Safety Monitoring Board for Eiger and Ionis; is a member of the Speakers Bureau for AbbVie, Bayer, Bristol-Myers Squibb, Dova, Eisai, Gilead Sciences, Intercept, Salix, and Shionogi; and has stock options with AngioCrine, Eiger BioPharma, and HepQuant.

: This article does not contain any studies with human or animal subjects performed by any of the authors.